Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 6 | 1 | 2 | N/A | N/A |
| Accounts receivable | -96 | 123 | 169 | -265 | -37 |
| Other Working Capital | -98 | 260 | 169 | -230 | 38 |
| Other Operating Activity | -635 | 516 | -1,171 | -1,327 | -2,096 |
| Operating Cash Flow | $-823 | $900 | $-831 | $-1,822 | $-2,095 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -52 | 6 | -9 | N/A | N/A |
| Other Investing Activity | 0 | 0 | -37 | 0 | 0 |
| Investing Cash Flow | $-52 | $6 | $-46 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -8 | 0 | -3 | N/A | N/A |
| Common Stock Issued | 0 | -449 | -1,044 | 2,346 | 1,478 |
| Other Financing Activity | 0 | -1,142 | 2,704 | 405 | 0 |
| Financing Cash Flow | $-8 | $-1,591 | $1,657 | $2,751 | $1,478 |
| Exchange Rate Effect | 8 | -3 | -47 | -24 | -35 |
| Beginning Cash Position | 2,463 | 3,151 | 4,018 | 1,562 | 2,214 |
| End Cash Position | 1,588 | 2,463 | 3,151 | 4,018 | 1,562 |
| Net Cash Flow | $-883 | $-685 | $780 | $880 | $-617 |
| Free Cash Flow | |||||
| Operating Cash Flow | -823 | 900 | -831 | -1,822 | -2,095 |
| Capital Expenditure | -52 | N/A | -9 | N/A | N/A |
| Free Cash Flow | -875 | 900 | -840 | -1,822 | -2,095 |